Analysis and data insight - Articles - Page 265

Money raised by biopharma: 2020 vs. 2019

April 3, 2020

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-April 2, 2020

April 3, 2020

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharma money raised by quarter in 2020 (US$M)

April 3, 2020

Biopharma money raised to-date and by quarter in 2019, including public, private and other financings.

Completed and pending biopharma IPOs in March 2020

April 3, 2020

Completed and pending initial public offerings by biopharma companies, including: Imara, Innocare Pharma.

Follow-on offerings of biopharma companies in March 2020

April 3, 2020

Follow-ons completed by biopharma companies, including: Baudax, Cel-Sci, Compugen, Hoth, Kala, Seelos, Tiziana Life Sciences, Zogenix.

Other financings of public biotechnology companies in March 2020

April 3, 2020

Private placements and other private financings of public biopharma companies, including: AB Science, Akari, Armata, Aytu, Baudax, Bellerophon, Biocurepharm, Brainstorm, Bridgebio, Cocrystal, Cytodyn, Emmaus Life Sciences, Enlivex, Equillium, Ethismos Research, Eton, Eyenovia, Helix, Hemostemix, IMV, Isofol Medical, Lattice, Marker, Moberg, Novan, Oncology Venture, Oncoquest, Pacylex, Plx, Predictive Oncology, Propanc, Protalix, Redx, Rockwell Medical, Theravance, Titan, Tonix, Unum, Vaccinex, Vaxart, Vaxil Bio, Verastem, Verrica, Vistagen, Xortx, Zosano.

Handshake, businessmen holding dollar sign, lightbulb

Med-tech deal and M&A values drop in Q1, significantly down from last year

April 3, 2020

By Karen Carey

A flurry of deal and M&A activity in the med-tech industry during the first quarter of 2020 has not translated into high financials, as many of the transactions are not disclosing terms. While the COVID-19 pandemic rages on, business development activities appear to be slumping in recent weeks, leaving the early part of the year significantly down from prior quarters.

Venture capital and other private biopharma financings in March 2020

April 3, 2020

Venture capital and other private financings of private biopharma companies, including: Abbisko, Advanced Biodesign, Affinia, Akouos, AM-Pharma, Amunix, Apexigen, Biosight, Castle Creek, Cinclus, Circle, Clarus, Design, Elevatebio, Eureka, Evonetix, Exuma, Harbour Biomed, Immunocore, Kallyope, Keros, Kymera, Lipidio, Nanjing Iaso, Numab, Nurix, Oncoone R&D, Onethree, Pliant, Polyprox, Primmune, Recode, Redpin, Regenacy, Sigilon, Silverback, Sutrovax, Svenska Vaccinfabriken Produktion, Syndivia, Tikomed, Xilio, Zucara.